Author + information
- S1936879815020798-d7e49c10f31da6d1147476b09442cbecDiego Arroyo,
- S1936879815020798-67f2d6aeca2631e2786da5ba34484fe2Zacharenia Kallinikou,
- S1936879815020798-6e317b9cb1f26c201c572b568ff66a51Nicloas Brugger,
- S1936879815020798-a7dbf065de561577396feaa1c9da6d79Nils Perrin,
- S1936879815020798-7ab84a361c4eb26d4f24fecc51adbd9dGerard Baeriswyl,
- S1936879815020798-67b3af66b44b8b51e8d9f4e842bdd899Jean-Jacques Goy,
- S1936879815020798-0e75fca960de33137b253c0293977befJean-Christophe Stauffer,
- S1936879815020798-1bf971f33ac68c0044767bfdd3c5da4aMario Togni,
- S1936879815020798-0ae74f5c5a757bb417d7db39032cfa96Stephane Cook and
- S1936879815020798-4c61a1b4c048e1ed4324260df7843280Serban Puricel
New-generation thin strut bioabsorbable polymer drug-eluting stents (DES) have shown promising mid-term results in clinical trials and real-world registries. We sought to assess 1-year efficacy and safety outcomes in all-comer patients treated with the SYNERGY stent at our institution.
All consecutive patients treated with the SYNERGY stent at University and Hospital Fribourg between January 2013 and March 2015 were prospectively included in the Fribourg SYNERGY registry. Clinical follow-up was performed at 1 year. Intermediate safety monitoring was performed in September 2015 in all patients and assessed the occurrence of stent thrombosis (ST). Overall lesion complexity was assessed by the SYNTAX Score. The primary endpoint was the Academic Research Consortium (ARC) defined device-oriented composite of cardiac death, myocardial infarction of the target vessel and clinically indicated target lesion revascularization at 1 year.
A total of 425 patients were enrolled in the registry. Mean age was 66±11 years and 73% (n=309) of treated patients were men. Diabetes was found in 23% (n=98) of patients. The clinical presentation at index procedure was acute coronary syndrome in 63% (n=267) of cases. Mean SYNTAX score was 15±9. Chronic total occlusions were treated in 6% (n=27) and left main coronary arteries in 3% (n=11) of patients. One-year follow-up was available in the first 264 patients. The primary endpoint occurred in 4.2% (n=11) of patients. Cardiac death occurred in 1.9% (n=5) of patients. The rate of target vessel MI was 1.5% (n=4). All target lesion revascularizations were clinically indicated and occurred in 2.7% (n=7) of cases.
Overall, definite stent thrombosis according to ARC criteria had occurred in 4 patients (0.9%) at the time of intermediate safety assessment (mean follow-up: 329±201 days). The rate of early and late ST were 0.7% (n=3) and 0.2% (n=1), respectively.
This single center experience confirms the excellent safety and efficacy profile of the bioabsorbable polymer-coated thin strut everolimus-eluting SYNERGY stent in daily clinical practice.